Pre-emptive drugs for schizophrenia show mixed results

05/1/2006 | NYTimes.com

Findings from the first long-term trial of the concept of prescribing drugs to young people at risk of schizophrenia, but not yet exhibiting the disorder, raised more questions than they answered, experts said. The study's lead author says there were only marginally significant positive results, while the weight gain involved in taking Eli Lilly's antipsychotic drug Zyprexa caused many participants to drop out of the study, skewing results.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX